spacer
home > ebr > spring 2017 > express yourself
PUBLICATIONS
European Biopharmaceutical Review

Express Yourself

EBR: Oxford Genetics offers numerous services in preclinical R&D. Can you tell us a little about some of these?

Paul Brooks: Oxford Genetics is a synthetic biology company that offers products and services to support the discovery, development and production of biologics, gene and cell therapies. We have tremendous expertise in designing DNA, optimising expression of proteins, improving viral delivery systems and cell line development.

In your opinion, what is the significance of the research undertaken at Oxford Genetics for the wider patient base, and how does it contribute to the production of new and efficacious vaccines?

Oxford Genetics is addressing some of the fundamental problems affecting the biopharmaceutical industry in relation to maximising productivity. We are helping to achieve cost-effective production of material for clinical testing and commercial manufacture from smaller batch sizes, which offers a viable route to market for therapies that might not otherwise make it.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Ryan Cawood is Chief Executive Officer and founder of Oxford Genetics. He established the company in 2011 with the aim to revolutionise DNA design, optimisation and assembly in order to enable molecular engineering to fulfil its promise in synthetic biology and medicine. Ryan’s research interests include vaccines and treatments for infectious diseases and cancer. He was inspired to create Oxford Genetics after observing that inefficient DNA design and assembly often limit scientific progress. Ryan has a degree in Genetics and a PhD from Oxford University, UK.

Paul Brooks is Commercial Director at Oxford Genetics. He recently joined the company from Sigma-Aldrich, where he was responsible for the commercialisation of their functional genomic technologies – including those for genome-editing. Over the course of his career, Paul has held various senior management positions in both the US and Europe, and has overseen the development, marketing and sales of genomic technologies, products and services. He holds a PhD in Molecular Biology from the University of Manchester, UK, and an MBA from the University of Nottingham, UK.
spacer
Ryan Cawood
spacer
spacer
spacer
Paul Brooks
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

ICON Announces Executive Leadership Transition


More info >>

White Papers

PROTEIN:PROTEIN INTERACTION ANALYSIS

IBA GmbH

Groth et al., 2007 and Jasencakova et al., 2010 Protein:protein-interactions (PPI) govern almost all important processes in living organisms. Thus, their rapid and accurate determination and investigation is a major challenge in life sciences. The extremely efficient and fast One-STrEP (Twin-Strep) system is suitable for the isolation of functional protein complexes and subsequent mass spectrometry analysis leads to the identification of protein complex components (Junttila et al., 2005) as it is shown in the following studies.
More info >>

 
Industry Events

Outsourcing in Clinical Trials Medical Devices 2017

27-28 June 2017, Santa Clara, CA

OCT Medical Devices moved to Irvine, California for the first year in 2016, and we are pleased to say it proved a resounding success. As the only event to cater for the Southern California Medical device hub in Irvine, it brought together a variety of medical device companies of all sizes, including Medtronic, Edwards Lifesciences, Onciomed, Inc and St Jude Medical.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement